Quoin receives FDA clearance to expand QRX003 trials; blinded trial to 30 subjects, dose changed to 4% twice daily

Quoin Pharmaceuticals, Ltd.

FDA cleared protocol amendments for both ongoing QRX003 trials for Netherton Syndrome.
Blinded trial increased from 18 to 30 subjects; lower 2% dose eliminated, all now receive 4% QRX003 or placebo twice daily.
Open-label trial expanded from 10 to 20 subjects; dosing frequency changed to twice daily with continued off-label systemic therapy.
Decision based on positive initial data and clean safety profile; all clinical endpoints unchanged.
Quoin plans to open additional clinical sites to accommodate increased enrollment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.